Citations

Clear

4 citation(s) found for "Shaffer, Richard".

American Radium Society (ARS) Appropriate Use Criteria (AUC) for Low-Dose Radiotherapy for Treatment of Osteoarthritis
Dove, Austin, Koneru, Bobby, Small, William, Nelson, Amanda E., Jeffries, Matlock, Bennion, Phillip, Jones, Craig, Campbell, S., Tendulkar, Rahul, Russo, Suzanne , Lester, Scott, Jethwa, Krishan, Hofstetter, Catherine , Appleton, Tom, Shaffer, Richard, Russo, Suzanne , Dove, Austin P.H. , Koneru, Bobby Nagendra , Small, William, Wright, Jean L. , Jeffries, Matlock Arizona

Mayo Clinic

American Journal of Clinical Oncology | May 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/coc.0000000000001333 | PMID 42184209 Get It

Objectives: To summarize current evidence for radiotherapy in the treatment of OA. The population, intervention, comparator, and outcome questions included: What is the role of LDRT for treatment of OA?; What are risks of LDRT?; and What are the optimal RT techniques for OA? Methods: This multispecialty-led committee includes radiation oncologists, rheumatologists, orthopedic surgeons, and a patient advocate. Using the population, intervention, comparator, outcome, timing and study design (PICOTS) framework, evidence regarding treatment outcomes was assessed using Cochrane and PRISMA methodology. Eligible studies included prospective and retrospective (n≥50) studies published between January 1, 2010, and May 10, 2025, from Embase, Medline, and PubMed databases. Study type and quality were assessed. Well-established RAND-UCLA consensus methodology (modified Delphi) was used to rate the appropriateness of the treatment options. Results: Of the 548 articles identified using the search strategy, 44 were selected for inclusion. Eight additional studies were identified through backward citation searching. Ten well-designed studies accounting for biases, 15 moderately well-designed studies accounting for the most common biases, 18 studies with design limitations, 8 supplemental studies not useful as primary evidence, and 1 meta-analysis were included. Additional studies were included to provide context and were not used to guide recommendations. The results of this analysis demonstrate that LDRT results in an overall treatment response rate of 60% to 90%, with significant clinical benefits including pain reduction, increased joint mobility, and improved quality of life. Conclusions: This systematic review and consensus guidelines for LDRT treatment of OA are based on current evidence. Further high-quality studies are warranted.
Stress Fractures of the Pelvis in Female Navy Recruits: An Analysis of Possible Mechanisms of Injury
Kelly, Edward W., Jonson, Scott R., Cohen, Mark E., Shaffer, Richard A.

Mayo Clinic

Military Medicine | March 9, 2018 | Volume: 165 | Issue: 2 | Pages: 142-146

10.1093/milmed/165.2.142 Get It

The Effect of Foot Structure and Range of Motion on Musculoskeletal Overuse Injuries
Brodine, Stephanie K., Shaffer, Richard A., Johnson, Chrisanna Weech, Cullison, Thomas R., Kaufman, Kenton R.

Mayo Clinic

The American Journal of Sports Medicine | July 19, 2017 | Volume: 27 | Issue: 5 | Pages: 585-593

10.1177/03635465990270050701 | PMID 10496574 Get It

The purpose of this prospective study was to determine whether an association exists between foot structure and the development of musculoskeletal overuse injuries. The study group was a well-defined cohort of 449 trainees at the Naval Special Warfare Training Center in Coronado, California. Before beginning training, measurements were made of ankle motion, subtalar motion, and the static (standing) and dynamic (walking) characteristics of the foot arch. The subjects were tracked prospectively for injuries throughout training. We identified risk factors that predispose people to lower extremity overuse injuries. These risk factors include dynamic pes planus, pes cavus, restricted ankle dorsiflexion, and increased hindfoot inversion, all of which are subject to intervention and possible correction.
Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
Shaffer, Brian C. , Ahn, Kwang Woo , Hu, Zhen‐Huan , Malone, Adriana K. , Valcárcel, David , Hamilton, Betty K. , Kharfan‐Dabaja, Mohamed A. , Saad, Ayman , Warlick, Erica D. , Wirk, Baldeep , Sabloff, Mitchell , Fasan, Omotayo , Gerds, Aaron T. , Marks, David I. , Olsson, Richard F. , Wood, William A. , Costa, Luciano J. , Miller, Alan M. , Cortes, Jörge E. , Daly, Andrew , Kindwall‐Keller, Tamila L. , Kamble, Rammurti T., Rizzieri, David A. , Cahn, Jean‐Yves , William, Basem M. , Litzow, Mark R. , Wiernik, Peter H. , Vij, Ravi , Üstün, Celalettin , Copelan, Edward A. , Kalaycio, Matt, Alyea, Edwin P. , Sobecks, R., Pavletic, Steven Z. , Tallman, Martin S. , Saber, Wael , Nishihori, Taiga , Bacher, Ulrike , Hamilton, Betty, Kharfan-Dabaja, Mohamed A., Cutler, Corey, Warlick, Erica, Wirk, Baldeep Mona, Marks, David, Olsson, Richard, Wood, William Allen, Cortes, Jorge, Kindwall-Keller, Tamila L, Kamble, Rammurti, William, Basem, Savani, Bipin N. , Copelan, Edward, Popat, Uday, Maziarz, Richard, Alyea, Edwin, Sobecks, Ron, Pavletic, Steven, Tallman, Martin, Grunwald, Michael R. , Cutler, Corey S. , Reshef, Ran , Gale, Robert Peter , Liesveld, Jane L. , Popat, Uday R , Maziarz, Richard Thomas , Gerds, Aaron T , Saad, Ayman , Olsson, Richard F , Cortes, Jorge , William, Basem , Costa, Luciano J , Sabloff, Mitchell , Wood, William A , Valcárcel, David

Mayo Clinic

Journal of Clinical Oncology | April 5, 2016 | Volume: 34 | Issue: 16 | Pages: 1864-1871

10.1200/jco.2015.65.0515 | PMID 27044940 Get It

Purpose To develop a system prognostic of outcome in those undergoing allogeneic hematopoietic cell transplantation (allo HCT) for myelodysplastic syndrome (MDS). Patients and Methods We examined 2,133 patients with MDS undergoing HLA-matched (n = 1,728) or -mismatched (n = 405) allo HCT from 2000 to 2012. We used a Cox multivariable model to identify factors prognostic of mortality in a training subset (n = 1,151) of the HLA-matched cohort. A weighted score using these factors was assigned to the remaining patients undergoing HLA-matched allo HCT (validation cohort; n = 577) as well as to patients undergoing HLA-mismatched allo HCT. Results Blood blasts greater than 3% (hazard ratio [HR], 1.41; 95% CI, 1.08 to 1.85), platelets 50 × 109/L or less at transplantation (HR, 1.37; 95% CI, 1.18 to 1.61), Karnofsky performance status less than 90% (HR, 1.25; 95% CI, 1.06 to 1.28), comprehensive cytogenetic risk score of poor or very poor (HR, 1.43; 95% CI, 1.14 to 1.80), and age 30 to 49 years (HR, 1.60; 95% CI, 1.09 to 2.35) were associated with increased hazard of death and assigned 1 point in the scoring system. Monosomal karyotype (HR, 2.01; 95% CI, 1.65 to 2.45) and age 50 years or older (HR, 1.93; 95% CI, 1.36 to 2.83) were assigned 2 points. The 3-year overall survival after transplantation in patients with low (0 to 1 points), intermediate (2 to 3), high (4 to 5) and very high (≥ 6) scores was 71% (95% CI, 58% to 85%), 49% (95% CI, 42% to 56%), 41% (95% CI, 31% to 51%), and 25% (95% CI, 4% to 46%), respectively (P < .001). Increasing score was predictive of increased relapse (P < .001) and treatment-related mortality (P < .001) in the HLA-matched set and relapse (P < .001) in the HLA-mismatched cohort. Conclusion The proposed system is prognostic of outcome in patients undergoing HLA-matched and -mismatched allo HCT for MDS.